SE9501881D0 - New pharmacological use of AII-receptor antagonists - Google Patents

New pharmacological use of AII-receptor antagonists

Info

Publication number
SE9501881D0
SE9501881D0 SE9501881A SE9501881A SE9501881D0 SE 9501881 D0 SE9501881 D0 SE 9501881D0 SE 9501881 A SE9501881 A SE 9501881A SE 9501881 A SE9501881 A SE 9501881A SE 9501881 D0 SE9501881 D0 SE 9501881D0
Authority
SE
Sweden
Prior art keywords
receptor antagonists
pct
new pharmacological
pharmacological use
aii receptor
Prior art date
Application number
SE9501881A
Other languages
English (en)
Inventor
Lars Faendriks
Anders Pettersson
Anders Aaneman
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9501881A priority Critical patent/SE9501881D0/sv
Publication of SE9501881D0 publication Critical patent/SE9501881D0/sv
Priority to ZA963569A priority patent/ZA963569B/xx
Priority to SK1513-97A priority patent/SK151397A3/sk
Priority to EE9700309A priority patent/EE03666B1/xx
Priority to KR1019970708250A priority patent/KR19990014905A/ko
Priority to JP8534742A priority patent/JPH11505243A/ja
Priority to CN96193988A priority patent/CN1093761C/zh
Priority to EP96914504A priority patent/EP0830131A1/en
Priority to CZ19973454A priority patent/CZ290155B6/cs
Priority to MX9708557A priority patent/MX9708557A/es
Priority to HU9900227A priority patent/HUP9900227A3/hu
Priority to AU57845/96A priority patent/AU706301B2/en
Priority to NZ308260A priority patent/NZ308260A/xx
Priority to PCT/SE1996/000602 priority patent/WO1996036336A1/en
Priority to RU97120700/14A priority patent/RU2194505C2/ru
Priority to BR9608407A priority patent/BR9608407A/pt
Priority to CA002219395A priority patent/CA2219395A1/en
Priority to US08/696,971 priority patent/US5900428A/en
Priority to IL11829996A priority patent/IL118299A/xx
Priority to MYPI96001899A priority patent/MY114428A/en
Priority to TW085106910A priority patent/TW473389B/zh
Priority to IS4597A priority patent/IS4597A/is
Priority to NO975221A priority patent/NO975221D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE9501881A 1995-05-19 1995-05-19 New pharmacological use of AII-receptor antagonists SE9501881D0 (sv)

Priority Applications (23)

Application Number Priority Date Filing Date Title
SE9501881A SE9501881D0 (sv) 1995-05-19 1995-05-19 New pharmacological use of AII-receptor antagonists
ZA963569A ZA963569B (en) 1995-05-19 1996-05-06 New pharmacological use of all-receptor antagonists
US08/696,971 US5900428A (en) 1995-05-19 1996-05-08 Pharmacological use of AII-receptor antagonists
HU9900227A HUP9900227A3 (en) 1995-05-19 1996-05-08 New pharmacological use of aii-receptor antagonists
PCT/SE1996/000602 WO1996036336A1 (en) 1995-05-19 1996-05-08 New pharmacological use of aii-receptor antagonists
KR1019970708250A KR19990014905A (ko) 1995-05-19 1996-05-08 Ａⅱ-수용체 길항제의 신규 약학적 용도
JP8534742A JPH11505243A (ja) 1995-05-19 1996-05-08 Ａｉｉ受容体アンタゴニストの新規な薬理学的使用
CN96193988A CN1093761C (zh) 1995-05-19 1996-05-08 Aii受体拮抗剂的新的药物用途
EP96914504A EP0830131A1 (en) 1995-05-19 1996-05-08 New pharmacological use of aii-receptor antagonists
CZ19973454A CZ290155B6 (cs) 1995-05-19 1996-05-08 Léčivo pro léčení několikanásobné poruchy systémových orgánů
MX9708557A MX9708557A (es) 1995-05-19 1996-05-08 Nuevo uso farmacologico de los antagonistas del receptor aii.
SK1513-97A SK151397A3 (en) 1995-05-19 1996-05-08 New pharmacological use of aii-receptor antagonists
AU57845/96A AU706301B2 (en) 1995-05-19 1996-05-08 New pharmacological use of AII-receptor antagonists
NZ308260A NZ308260A (en) 1995-05-19 1996-05-08 Use of 5-(substituted biphenyl)-tetrazole derivatives to treat multiple system organ failure
EE9700309A EE03666B1 (et) 1995-05-19 1996-05-08 AII-retseptori antagonistide uus farmakoloogilinekasutus
RU97120700/14A RU2194505C2 (ru) 1995-05-19 1996-05-08 Новое фармакологическое применение антагонистов а-ii рецептора
BR9608407A BR9608407A (pt) 1995-05-19 1996-05-08 Uso de um composto preparação farmacéutica para uso na profilaxa e/ou tratamento de insuficiência de orgãos múltiplos sistemas e processo para profilaxia e tratamento de insuficiência de órgãos de múltiplos sistemas em mamíferos incluindo homem
CA002219395A CA2219395A1 (en) 1995-05-19 1996-05-08 New pharmacological use of aii-receptor antagonists
IL11829996A IL118299A (en) 1995-05-19 1996-05-16 Use of AII-receptor antagonists for the manufacture of a medicament with effect on multiple system organ failure
MYPI96001899A MY114428A (en) 1995-05-19 1996-05-18 New pharmacological use of aii-receptor antagonists
TW085106910A TW473389B (en) 1995-05-19 1996-06-08 New pharmacological use of AII-receptor antagonists
IS4597A IS4597A (is) 1995-05-19 1997-10-22 Ný lyfjafræðileg notkun AII-viðtaka mótlyfja
NO975221A NO975221D0 (no) 1995-05-19 1997-11-13 Ny farmakologisk anvendelse av AII-reseptorantagonister

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9501881A SE9501881D0 (sv) 1995-05-19 1995-05-19 New pharmacological use of AII-receptor antagonists

Publications (1)

Publication Number Publication Date
SE9501881D0 true SE9501881D0 (sv) 1995-05-19

Family

ID=20398385

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9501881A SE9501881D0 (sv) 1995-05-19 1995-05-19 New pharmacological use of AII-receptor antagonists

Country Status (23)

Country Link
US (1) US5900428A (sv)
EP (1) EP0830131A1 (sv)
JP (1) JPH11505243A (sv)
KR (1) KR19990014905A (sv)
CN (1) CN1093761C (sv)
AU (1) AU706301B2 (sv)
BR (1) BR9608407A (sv)
CA (1) CA2219395A1 (sv)
CZ (1) CZ290155B6 (sv)
EE (1) EE03666B1 (sv)
HU (1) HUP9900227A3 (sv)
IL (1) IL118299A (sv)
IS (1) IS4597A (sv)
MX (1) MX9708557A (sv)
MY (1) MY114428A (sv)
NO (1) NO975221D0 (sv)
NZ (1) NZ308260A (sv)
RU (1) RU2194505C2 (sv)
SE (1) SE9501881D0 (sv)
SK (1) SK151397A3 (sv)
TW (1) TW473389B (sv)
WO (1) WO1996036336A1 (sv)
ZA (1) ZA963569B (sv)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW580397B (en) * 1997-05-27 2004-03-21 Takeda Chemical Industries Ltd Solid preparation
US6514249B1 (en) 1997-07-08 2003-02-04 Atrionix, Inc. Positioning system and method for orienting an ablation element within a pulmonary vein ostium
SE9800550D0 (sv) * 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
JP3746167B2 (ja) * 1998-05-18 2006-02-15 武田薬品工業株式会社 医薬製剤
EP1561458B1 (en) 1998-07-28 2010-09-15 Takeda Pharmaceutical Company Limited Rapidly disintegrable solid preparation
US6833381B2 (en) 2000-02-18 2004-12-21 Takeda Chemical Industries, Ltd. TNF-α inhibitors
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
KR20130074808A (ko) 2011-12-16 2013-07-05 한올바이오파마주식회사 스타틴계 지질저하제에 의한 근육계 부작용의 치료 또는 예방을 위한 로사르탄을 포함하는 약제학적 조성물
CN104261284B (zh) * 2014-09-18 2016-02-03 中邮建技术有限公司 一种无线基站的天线吊装装置
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides

Also Published As

Publication number Publication date
RU2194505C2 (ru) 2002-12-20
NZ308260A (en) 2000-12-22
TW473389B (en) 2002-01-21
SK151397A3 (en) 1998-08-05
IS4597A (is) 1997-10-22
WO1996036336A1 (en) 1996-11-21
NO975221L (no) 1997-11-13
JPH11505243A (ja) 1999-05-18
IL118299A (en) 2000-07-26
HUP9900227A3 (en) 2002-11-28
HUP9900227A2 (hu) 2000-03-28
AU5784596A (en) 1996-11-29
KR19990014905A (ko) 1999-02-25
EP0830131A1 (en) 1998-03-25
AU706301B2 (en) 1999-06-10
MY114428A (en) 2002-10-31
CN1093761C (zh) 2002-11-06
EE9700309A (et) 1998-06-15
CZ290155B6 (cs) 2002-06-12
BR9608407A (pt) 1998-12-29
CA2219395A1 (en) 1996-11-21
MX9708557A (es) 1997-12-31
EE03666B1 (et) 2002-04-15
NO975221D0 (no) 1997-11-13
CZ345497A3 (cs) 1998-03-18
ZA963569B (en) 1996-11-19
CN1184424A (zh) 1998-06-10
IL118299A0 (en) 1996-09-12
US5900428A (en) 1999-05-04

Similar Documents

Publication Publication Date Title
PT893992E (pt) Formas de dosagem oral de desintegracao rapida
SE9500422D0 (sv) New oral pharmaceutical dosage forms
TR199802698T2 (xx) Valsartan�n kat� oral doz formlar�.
HU9603228D0 (en) Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
DE69532580D1 (de) Neue antagonistische verbindungen
ES2185660T3 (es) Nuevo uso de dexmedetomidina.
SE9501881D0 (sv) New pharmacological use of AII-receptor antagonists
BR9509975A (pt) Formulação farmacêutica
IS1961B (is) Notkun 1-(2-naft-2-ýletýl)-4(3-tríflúorómetýlfenýl)-1,2,3,6-tetrahýdrópýridíns til gerðar lyfja tilþess að meðhöndla hliðarstrengjahersli
SE9600120D0 (sv) Novel medical use
ZA954643B (en) Endoparasiticides
DK0866711T3 (da) Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö
EE9700366A (et) Angiotensiini II tüüp 1 retseptori antagonistide kasutamine düspeptiliste sümptomite profülaktikas ja/või ravis kasutatava ravimi valmistamiseks ja angiotensiini II tüüp 1 retseptori antagoniste sisaldavad ravimpreparaadid
SE9404438D0 (sv) New process
DK0648117T3 (da) Lægemiddel til at forebygge udvikling af tolerance ved behandling med benzodiazepin-receptor-bindende aktive forbindelser
SE9500897D0 (sv) The pharmacological use of certain cystine derivatives
DK0850225T3 (da) Mellemprodukt til fremstilling af en farmaceutisk aktiv forbindelse